◼ Archived
Business
🔮 fades ✗
Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
3 trends tracked about this subject — the full history, oldest to newest below.
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.
Pfizer's Phase 3 trial for the lung cancer drug Sigvotatug Vedotin failed to meet its primary endpoint for survival.
Definium Therapeutics' LSD-based depression treatment shows promising results in a pivotal trial, driving stock surge